BACKGROUND: Tumors invading the depth of adventitia (T3) are the most common pathological type of esophageal squamous cell carcinoma (ESCC). For patients without lymph nodes metastasis, the role of adjuvant therapy is uncertain. This study was intended to retrospectively analyze the survival effects of postoperative adjuvant therapy in such patients. METHODS: A total of 200 patients with pathological T3N0M0 (pT3N0M0) ESCC from January 2012 to September 2014 were enrolled, including a surgery-alone group (Group S) of 111 patients and a surgery followed with adjuvant chemo/radiation/chemoradiation therapy group (Group S + aCRT) of 89 patients. RESULTS: There was no significant difference in preoperative basic characteristics and postoperative complications between the two groups. Among all patients, 5-year overall survival (OS) rate was 56.6% and the 5-year disease-free survival (DFS) rate was 51.1%, respectively. The 5-year OS rate was 47.2% in Group S, and 68.4% in Group S + aCRT (P=0.004). The 5-year DFS rate was 44.4% in Group S and 59.3% in Group S + aCRT (P=0.036). The 5-year OS and DFS were improved by adjuvant chemoradiotherapy in the subgroups of males, tumor located at the middle of thoracic esophagus, moderate differentiation, number of resected lymph nodes <15. Multivariate analysis showed that adjuvant chemoradiotherapy and female were associated with improved survival. CONCLUSIONS: In our study, the adjuvant therapy was associated with improved survival for patients with pT3N0M0 ESCC.
BACKGROUND: Tumors invading the depth of adventitia (T3) are the most common pathological type of esophageal squamous cell carcinoma (ESCC). For patients without lymph nodes metastasis, the role of adjuvant therapy is uncertain. This study was intended to retrospectively analyze the survival effects of postoperative adjuvant therapy in such patients. METHODS: A total of 200 patients with pathological T3N0M0 (pT3N0M0) ESCC from January 2012 to September 2014 were enrolled, including a surgery-alone group (Group S) of 111 patients and a surgery followed with adjuvant chemo/radiation/chemoradiation therapy group (Group S + aCRT) of 89 patients. RESULTS: There was no significant difference in preoperative basic characteristics and postoperative complications between the two groups. Among all patients, 5-year overall survival (OS) rate was 56.6% and the 5-year disease-free survival (DFS) rate was 51.1%, respectively. The 5-year OS rate was 47.2% in Group S, and 68.4% in Group S + aCRT (P=0.004). The 5-year DFS rate was 44.4% in Group S and 59.3% in Group S + aCRT (P=0.036). The 5-year OS and DFS were improved by adjuvant chemoradiotherapy in the subgroups of males, tumor located at the middle of thoracic esophagus, moderate differentiation, number of resected lymph nodes <15. Multivariate analysis showed that adjuvant chemoradiotherapy and female were associated with improved survival. CONCLUSIONS: In our study, the adjuvant therapy was associated with improved survival for patients with pT3N0M0 ESCC.
Entities:
Keywords:
Esophageal squamous cell carcinoma (ESCC); T3N0M0; adjuvant chemoradiotherapy; surgery
Authors: W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: P Flamen; E Van Cutsem; A Lerut; J P Cambier; K Haustermans; G Bormans; P De Leyn; D Van Raemdonck; W De Wever; N Ectors; A Maes; L Mortelmans Journal: Ann Oncol Date: 2002-03 Impact factor: 32.976
Authors: Robert James Cerfolio; Ayesha S Bryant; Buddhiwardhan Ohja; Alfred A Bartolucci; Mohamad A Eloubeidi Journal: J Thorac Cardiovasc Surg Date: 2005-06 Impact factor: 5.209
Authors: Shawn S Groth; Beth A Virnig; Bryan A Whitson; Todd E DeFor; Zhong-Ze Li; Todd M Tuttle; Michael A Maddaus Journal: J Thorac Cardiovasc Surg Date: 2009-08-25 Impact factor: 5.209
Authors: Christian G Peyre; Jeffrey A Hagen; Steven R DeMeester; Nasser K Altorki; Ermanno Ancona; S Michael Griffin; Arnulf Hölscher; Toni Lerut; Simon Law; Thomas W Rice; Alberto Ruol; Jan J B van Lanschot; John Wong; Tom R DeMeester Journal: Ann Surg Date: 2008-10 Impact factor: 12.969
Authors: Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar Journal: Ann Surg Date: 2008-08 Impact factor: 12.969